Clinical Trials (PDQ®) - National Cancer Institute

Page Options

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?


	1-800-4-CANCER

	LiveHelp online chat

	NCI Highlights


	Maintenance Rituximab for Follicular Lymphoma Azacitidine Improves Survival in MDS Second Stem Cell Transplant Not Helpful in Myeloma

Immunotherapy with BCG with or without Irradiated Allogeneic Cells for Stage I Lung Carcinoma

Basic Trial Information
Objectives
Entry Criteria
Expected Enrollment
Outline
Trial Contact Information

Basic Trial Information

Phase Type Status Age Sponsor Protocol IDs
No phase specified Treatment Closed no age specified NCI-LUN-1

Objectives

I.  Investigate therapeutic efficacy of BCG and BCG plus irradiated allogeneic 
cells in patients with Stage I carcinoma of the lung.
II.  Correlate in vitro and in vivo measurements of cellular immunity with the 
clinical status of patients.

Entry Criteria

Disease Characteristics:

See General Eligibility Criteria

Patient Characteristics:

See General Eligibility Criteria

General Eligibility Criteria:

Patients with resected lung cancer, 
Stage I according to surgical and pathological information, within 1 month of 
surgery.

Expected Enrollment

Protocol closed as of June 1979 with 100 patients accrued.

Outline

Randomized study.
Arm I:  No further therapy.
Arm II:  Single-agent Immunotherapy.  BCG-Pasteur, BCG, NSC-116328.
Arm III:  Single-agent Immunotherapy plus Irradiated Tumor Cells.  BCG; 
x-irradiated lung tumor cells.

Trial Contact Information

Trial Lead Organizations

UPMC Cancer Centers

Ronald Herberman, MD, Protocol chair
Ph: 412-623-3205
Email: herbermanb@upmc.edu

Note: The purpose of most clinical trials listed in this database is to test new cancer treatments, or new methods of diagnosing, screening, or preventing cancer. Because all potentially harmful side effects are not known before a trial is conducted, dose and schedule modifications may be required for participants if they develop side effects from the treatment or test. The therapy or test described in this clinical trial is intended for use by clinical oncologists in carefully structured settings, and may not prove to be more effective than standard treatment. A responsible investigator associated with this clinical trial should be consulted before using this protocol.